# Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine

> **NCT00994695** · PHASE2 · COMPLETED · sponsor: **Armauer Hansen Research Institute, Ethiopia** · enrollment: 412 (actual)

## Conditions studied

- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** Mencevax ACW Vaccine

## Key facts

- **NCT ID:** NCT00994695
- **Lead sponsor:** Armauer Hansen Research Institute, Ethiopia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-01
- **Final completion:** 2007-11
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2009-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994695, "Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00994695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*